Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIa dose-regimen study of SKLB1028 capsules in FLT3-mutated relapsed or refractory acute myeloid leukemia
ChiCTR1900025190Phase 2Recruiting
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology
- Start
- Jul 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of ruserontinib in acute myeloid leukemia (AML) (3 arms), sponsored by CSPC ZhongQi Pharmaceutical Technology. Primary endpoint: Overall response rate. Started Jul 2019; status: recruiting.
02
Drugs
ruserontinib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on ChiCTR1900025190.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900025190.